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Regulatory mechanisms for angiogenesis are relatively well established compared to lym-
phangiogenesis. Few studies have shown that a combination of vascular endothelial growth
factor VEGF-A/C with hypoxia or collagen matrix promotes lymphatic structures along with
blood vessel development in mouse embryoid bodies (EB). In this study we tested the
hypothesis that while hypoxia combined with prolongedVEGF-A/C treatment would induce
early lymphangiogenesis in addition to angiogenesis inmouseEBs, under similar conditions
speciﬁc extracellular matrix (ECM) proteins would promote lymphatic vessel-like structures
over angiogenesis. EBs were subjected to four conditions and were maintained under nor-
moxia and hypoxia (21% and 2.6% O2, respectively) with or without VEGF-A/C. Microarray
analyses of normoxic and hypoxic EBs, and immunoﬂuorescence data showed very low
expression of early lymphatic endothelial cell (LEC) markers, lymphatic vessel endothe-
lial hyaluronan receptor 1 (LYVE1), and prospero-related homeobox 1 (Prox1) at early time
points. Double immunoﬂuorescence using MECA-32 and Prox1/LYVE1 demonstrated that
combined hypoxia and VEGF-A/C treatment promoted formation of blood vessel-like struc-
tures, whereas only Prox1+/LYVE1+ LECs were detected in EBs at E22.5. Furthermore,
EBs were grown on laminin or collagen-I coated plates and were subjected to the four
treatments as described above. Results revealed that LECs in EBs at E36.5 attached better
to collagen-I, resulting in an organized network of lymphatic vessel-like structures as com-
pared to EBs grown on laminin. However, blood vessel-like structures were less favored
under these same conditions. Collectively, our data demonstrate that hypoxia combined
with growth factors promotes angiogenesis, whereas combination of these conditions
with speciﬁc ECM proteins favors lymphangiogenesis processes in mouse EBs.
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INTRODUCTION
The lymphatic system is a specialized vasculature that is intimately
involved in body ﬂuid circulation, macromolecular homeostasis,
lipid absorption, and immune function. Interstitial ﬂuid enters
via lymphatic capillaries and is transported into the venous cir-
culation via larger collecting lymphatics, which are comprised
of muscle and adventitial layers wrapped around the endothelial
tube (Schmid-Schonbein, 1990; Borisov, 2005). Lymphaticmuscle
exhibits important differences from typical vascular smooth mus-
cle that are critical to overall lymphatic function (Muthuchamy
et al., 2003). Thephasic and tonic contractility of lymphaticmuscle
function is essential for lymph propulsion and transport (Gashev
et al., 2002, 2004).A dysfunctional lymphatic circulation can result
in a wide range of clinical disorders including edema, altered lym-
phocyte circulation, depressed immune function, impaired lipid
metabolism, etc. Primary impairment of lymphatic function pro-
duces lymphedema, which can be the result of numerous known
pathologies such as lymphatic ﬁlariasis, post surgical resection
of lymph nodes and lymphatics, and inﬂammatory processes.
Though several studies have unraveled the mechanisms by which
lymphangiogenesis promotes new lymphatic growth in tissues
with lymphedema, there are few efﬁcacious therapies, as well as
a nearly complete lack of medical treatment options for lym-
phatic dysfunction (Szuba and Rockson, 1998; Rockson, 2006).
In large part, this is due to the relatively poor understanding of
the mechanisms of lymphatic vessel development, particularly
lymphangiogenesis and muscle cell recruitment processes, and
lymphatic vessel functions.
In the last decade, several studies have elucidated key genes
involved in different stages of embryonic lymphangiogenesis in
mammals (Oliver, 2004; Oliver and Alitalo, 2005), including lym-
phatic vessel endothelial hyaluronan receptor 1 (LYVE1), tran-
scription factor prospero-related homeobox 1 (Prox1), and vas-
cular endothelial growth factor receptor 3 (VEGFR-3) amongst
several others (Kaipainen et al., 1995; Banerji et al., 1999; Wigle
and Oliver, 1999; Hong et al., 2002; Wigle et al., 2002). LYVE1
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contributes to lymphatic endothelial cell (LEC) competence and
its embryologic expression is observed around E9.0–E9.5 (Banerji
et al., 1999). Prox1 (Wigle and Oliver, 1999; Hong et al., 2002;
Wigle et al., 2002), which is expressed at E9.5–E10.5, is the master
regulator of LEC fate and is critical to lymphatic bias. In addition,
lymphatic speciﬁcation occurs at E12.5 days (Oliver, 2004; Oliver
and Alitalo, 2005); during which LEC differentiation is detected
along with the expression of VEGFR-3 (Kaipainen et al., 1995;
Dumont et al., 1998). Furthermore additional regulatory mole-
cules, such as Podoplanin (Schacht et al., 2003; Navarro et al.,
2008), neuropilin-2 (Yuan et al., 2002) angiopoietin-2 (Gale et al.,
2002; Veikkola and Alitalo, 2002), and ephrinB2 (Adams et al.,
1999; Makinen et al., 2005) have been shown to be involved in the
development of early and postnatal lymphatic vasculature.
In spite of the importance of these several molecular markers
for early lymphatic vessel development, themolecularmechanisms
that regulate this complex process are not yet completely under-
stood. Gene knockout studies on several lymphatic endothelial
markers (Jeltsch et al., 1997; Dumont et al., 1998; Karkkainen
et al., 2004) revealed the necessity of these genes in early lymphatic
endothelial differentiation and vessel development but failed to
provide a model to study their regulatory mechanisms since most
of the targeted mice are either embryonically or perinatally lethal.
To overcome the problems associated with knockout models, sev-
eral studies addressed the molecular mechanisms of early devel-
opmental processes by comparing the differentiation of mouse
embryonic stem (ES) cell-derived embryoid bodies (EB) fromwild
type and knockout ES cell lines. Liersch et al. (2006) demonstrated
that in the absence of VEGF-A/C, normoxic E27-day-old EBs
developed both blood and lymphatic structures. However, adding
VEGF-A or VEGF-C to the media potently promoted lymphatic
vessel formation. Kreuger et al. (2006) established that normoxic
E18-day-old EBs cultured in 3D collagen matrices and supple-
mented with VEGF-A/C formed lymphatic vessel-like structures,
and that hypoxia had little or no effect on the development of
early lymphatics. Recently Cueni et al. (2010) emphasized the
role for podoplanin in inhibiting lymph vessel formation in E22-
day-old mouse EBs grown in the presence of VEGF-A/C. These
data indicate that the mouse EB model could recapitulate early
stages of lymphatic vessel formation given the right environmen-
tal triggers, such as growth factors and extracellular matrix (ECM)
proteins. Taken together, we propose that while prolonged VEGF-
A/C treatment would induce both early lymphangiogenesis and
angiogenesis in mouse EBs, other environmental cues like ECM
proteins would differentially promote lymphatic or blood vessel
formation.
In the present study, we ﬁrst performed microarray analyses
in developing EBs to compare the gene expression patterns that
occurred during the processes of angiogenesis and lymphangio-
genesis. Then we tested the combined effects of oxygen treat-
ments, presence or absence of VEGF-A/C, and the presence or
absence of ECM proteins (collagen-I and laminin) in promot-
ing the formation of blood or lymphatic vessel-like structures in
mouse EBs.
MATERIALS AND METHODS
CELL CULTURE AND ESTABLISHMENT OF MOUSE EMBRYOID BODY
MODEL
Embryonic stem cells derived from 129/SvJ mice were cultured on
a feeder layer of mitotically inactivated primarymouse embryonic
ﬁbroblasts, as we have described previously (Ezekiel, 2007). The ES
cells were maintained in an undifferentiated state by supplement-
ing the ES media with leukemia inhibitory factor (LIF; Chemicon
International, Temecula, CA, USA). After three passages, ES cell
differentiation was achieved by the removal of ﬁbroblasts and
LIF. A schematic of the EB model is illustrated in Figure 1. At
E3.5, EBs were maintained in normoxia (21%O2) in 100mm bac-
terial culture plates (Corning Incorporated, Corning, NY, USA)
FIGURE 1 | Schematic illustration of the embryoid body (EB) model.The ES cell and EB culture conditions, and the durations of growth factors and hypoxic
conditions have been described in the Section “Materials and Methods.” EBs were maintained in normoxia at 21% O2 and hypoxic EBs were maintained at
2.6% O2.
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and cultured with Dulbecco modiﬁed Eagle medium (DMEM;
Gibco, Eggenstein, Germany) containing 4,500mg/L d-glucose, l-
glutamine, pyridoxine hydrochloride, and 25mM HEPES buffer.
DMEM was additionally supplemented with 15% fetal bovine
serum (FBS; Gibco), 1.2mM sodium pyruvate (Gibco), 0.12%
monothioglycerol (Sigma, St. Louis, Missouri), and 1% antibi-
otic/antimycotic (Gibco). For the microarray and real-time PCR
experiments (scheme not shown in Figure 1), EBswere transferred
on days E8, E12, E15, and E18 to hypoxia (2.6%O2) ormaintained
in normoxia. After 2 days of differential oxygen treatments, these
EBs were analyzed at E10, E14, E17, and E20 respectively. Hypoxia
was achieved in a humidiﬁed chamber ﬂushed with a mixture of
95% N2/5% CO2 gas and room air until the oxygen level was
stably maintained at 2.6%. For the immunohistochemistry (IHC)
experiments (scheme shown in Figure 1), at E10.5, EBs were trans-
ferred to 35mm plates and half the EBs was maintained in media
supplemented with recombinant human VEGF-A (R&D Systems,
Minneapolis, MN, USA; 20 ng/ml) and VEGF-C (R&D Systems;
100 ng/ml). To test the effects of short-term hypoxia, some EBs
with/without VEGF-A/C was transferred to hypoxia on E19.5 and
analyzed at E22.5. For long-term hypoxia experiments, some EBs
received VEGF-A/C at E10.5, further all EBs at E17.5 were seeded
onto a layer of either collagen-I (Sigma; 50μg/ml) or laminin
(Sigma; 20μg/ml). Thereafter some EBs with/without VEGF-A/C
was transferred to hypoxia on E26.5 and analysis was performed
at E36.5.
DOUBLE IMMUNOFLUORESCENCE AND MICROSCOPY
Embryoid bodies cultures were ﬁxed with 2% paraformaldehyde
(Sigma) for 1 h at room temperature (RT) followed by perme-
abilization with ice-cold methanol for 5min at 4˚C. EB samples
were then incubated with blocking solution containing 1% BSA
(Vector Laboratories, UK) and 5% Normal Goat Serum (RDI,
Concord, MA, USA) for 1 h/RT. These were treated with primary
antibodies (MECA-32,BDBiosciences; Prox1,Abcam,Cambridge,
MA, USA; LYVE1, Abcam) and appropriate secondary antibodies
(Oregon Green 488, Molecular Probes, Invitrogen; Cy5, Abcam).
Samples were mounted onto glass slides using Prolong antifade
solution (Molecular Probes, Invitrogen). Average projections were
produced from a 3D series of sections, where each 0.5μm thick
slice was imaged using the Leica AOBS SP2 Confocal microscope
with either a U APO 40× water objective of numerical aperture
1.15 or a 20×dry objective of numerical aperture 0.75. Each exper-
iment set was repeated three times for the set of marker genes and
we sampled various regions of EBs from different replicates within
a condition.
RNA ISOLATION
Total RNAwas isolated fromEBs (E14,E17,E20) usingRNASTAT-
60 (Tel-Test Inc., Friendswood, TX, USA). Brieﬂy, cells were lysed
in RNA STAT-60 by repetitive pipetting. Then chloroform was
added to separate the lysate into an aqueous phase containing
exclusively the total RNA and an organic phase containing DNA
andother proteins. The total RNAwasprecipitatedout by the addi-
tion of isopropanol, further washed with ethanol and solubilized
in water. The RNA was subsequently DNase treated with DNA-
free™(Ambion, Austin, TX, USA) and analyzed for both quality
and quantity using the Agilent 2100 Bioanalyzer and RNA6000
Nano LabChip Kit (Agilent Technologies).
REAL-TIME POLYMERASE CHAIN REACTION (RT-PCR)
cDNA was synthesized using the iScript cDNA synthesis kit (Bio-
Rad, Hercules, CA, USA). PCR primers for MECA-32, Prox1,
LYVE1, VEGFR-3, and GAPDH were designed using the Bea-
con Designer v6.0 software (PREMIER Biosoft International, Palo
Alto, CA,USA) and all primers were ordered from SigmaGenosys.
cDNA of Universal Mouse Reference RNA (UMRR) and EB sam-
ples were mixed with appropriate primers and SYBR Green super-
mix (BioRad) and ampliﬁed using the iCycler iQ Real-Time PCR
Detection System (BioRad). Quantiﬁcation of the real-time PCR
data was performed using the delta-delta Ct (ΔΔCt) model. In
this model, the quantity of each RNA transcript in each EB sample
was compared to that of GAPDH in the same sample to obtain
ΔCt values. These values were then normalized relative to a refer-
ence sample,UniversalMouseReferenceRNA (UMRR; Stratagene,
La Jolla, CA, USA) to obtain ΔΔCt values. Experiments were
performed four times for statistical analysis.
BOOTSTRAP STATISTICS
Gene expression fold changes were compared using permutation
tests (Hyde et al., 2007), in which, data from each gene were resam-
pled randomly with replacement,without regard to type of oxygen
treatment. Sample and calibrator values for both target and refer-
ence (GAPDH) genes were permuted independently to permit the
variance of both technical and biological replicates to be expressed
in the results. Following each reordering of the data, the ratio of
fold changes was calculated in the samemanner as was used for the
unordereddata,and the results stored to formanewdistributionof
1000 resampled ratios. The fraction of the permuted distribution
whose values exceeded the original (non-permuted)N/H ratiowas
then used to compute the probability that the observed N/H ratio
occurred by chance. Permutation tests are considered superior to
ANOVA or t -tests for small samples, or when sample distributions
are non-normal, as they entail no assumptions regarding the form
of the statistical distribution. Calculationswere performed on data
in the form of N/H fold-increase ratios. Comparisons of p-values
between tests using fold-increase ratios for the four genes over the
three embryonic days were highly correlated (r = 0.999), indicat-
ing the test results were not affected by the method of calculation
or the shape of the sample distribution. All data resampling oper-
ations were performed using the S-PLUS programming language,
v. 7.02 (Insightful Corp., Seattle,WA, USA).
MICROARRAY
Total RNA was ampliﬁed using the Amino Allyl MessageAmp
aRNA kit (Ambion). The aRNA ampliﬁcation procedure begins
with ﬁrst strand cDNA synthesis where total RNA is reverse tran-
scribed using an oligo(dT) primer containing a T7 RNA poly-
merase promoter sequence. The resulting cDNA then undergoes
second strand synthesis serving as a template for in vitro tran-
scription, which generates hundreds of antisense RNA (aRNA)
with incorporated modiﬁed nucleotide 5-(3-aminoallyl)-UTP
(aaUTP). The yield and quality of aRNA is assessed using the Agi-
lent 2100 Bioanalyzer (Agilent Technologies). The aRNA is then
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chemically dye-coupled toNHS esters of CY5dye (AmershamBio-
sciences, Piscataway, NJ, USA). UMRR (Stratagene, La Jolla, CA,
USA) was ampliﬁed in a similar manner and labeled with NHS
ester-Cy3 (Amersham Biosciences). The dye-coupled RNA sam-
ples were hybridized to glass arrays containing the Operon Mouse
Genome Oligo Set Version 3.0 containing 36K oligos (fabricated
in our departmental core lab). Following hybridization, the arrays
were scanned at 532 nmand 635 nmwavelengthswith a 10μmres-
olution using a GenePix 4000A scanner (Axon Instruments). The
two individual wavelength scans are then integrated and super-
imposed into a color ratio image (Red vs. Green). The acquired
raw data was transformed, normalized and ﬁltered using Gene-
Spring GX v7.3.1 software (Agilent Technologies). Differential
gene expression was assessed using Welsh ANOVAs and two-
sample t -tests (false discovery rate <0.05) followed by a two-fold
change restriction.
RESULTS
EFFECTS OF SHORT-TERM HYPOXIA ON GENE EXPRESSION PROFILES
OF MOUSE EBs AT DIFFERENT DAYS OF EMBRYONIC DEVELOPMENT
The data discussed in this publication have been deposited
in NCBI’s Gene Expression Omnibus and are acces-
sible through GEO Series accession number GSE17613
(http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE17613).
Microarray data from the EBs under normoxic and hypoxic condi-
tions identiﬁed a total of 357 and 995 genes, respectively that were
signiﬁcantly up- or down-regulated (p< 0.05 by at least twofold
across any of the time points E10, E14, E17, and E20. Selective
genes from the total of 357 and 995 genes are listed in Table 1 and
2, respectively. These include a host of growth factors, transcrip-
tion factors, and contractile proteins associated with angiogenesis
and cardiogenesis. Genes that respond to hypoxic conditions, like
ERO-1 was upregulated with hypoxic treatment, indicating that
the conditions we employed provided a hypoxic environment.
In addition, several set of genes that are related to cell growth,
development and cell–cell signaling were differentially regulated
in response to both oxygen treatments (data not shown). In this
study, we focused on the angiogenesis and lymphangiogenesis
processes in developing EBs.
Vascular endothelial growth factor receptor 1 (VEGFR-1) and
vascular endothelial growth factor A (VEGF-A) were upregulated
in EBs subjected to hypoxia between E10 and E20 (Table 2). Fur-
thermore differential expression patterns of contractile proteins is
observed between hypoxic and normoxic EBs (Tables 1 and 2).
However, differences in lymphatic markers and genes responsi-
ble for early lymphatic vessel formation such as Prox1, LYVE1,
VEGFR-3, Tie2, Podoplanin, and those involved in vessel/network
maturation and valve formation such as Syk/SLP76 and FoxC2
were not statistically signiﬁcant in either oxygen treatments. The
raw normalized values for these genes from the microarray data
have been reported in Table 3. Quantitative-PCR (qPCR) analyses
of gene expression for selective LEC markers, including LYVE1,
VEGFR-3, and Prox1, and blood endothelial cell (BEC) marker,
MECA-32 during EB development under normoxic and hypoxic
conditions are shown in Figure 2. Results demonstrate that both
blood and lymphatic marker genes are signiﬁcantly upregulated
under normoxic conditions compared to hypoxic conditions.
Figure 3A shows positive staining for both BECs and LECs
in normoxic (N) EBs. Hypoxic EBs formed MECA-32+ blood
vessel-like structures that were usually densely localized in one
small region within a single EB (Figure 3B). In addition early
LEC differentiation (Prox1+ cells) was detected in hypoxic EBs in
close vicinity to these blood vessel-like structures (arrowheads in
Figure 3B).
STIMULATION WITH VEGF-A/C PREFERENTIALLY PROMOTES
FORMATION OF BLOOD VESSEL-LIKE STRUCTURES IN E22.5-DAY-OLD
EBs
Figure 4 shows the light microscope images of E22.5-day-old EBs
under VEGF-A/C-treated normoxic (N+VEGF-A/C) andVEGF-
A/C-treated hypoxic (H+VEGF-A/C) conditions as described in
the Section “Materials and Methods.” EB cultures revealed exten-
sion and contact of adjacent EBs to form cord-like structures,
indicatedby arrowheads inFigure 4. Furthermoreunder both con-
ditions,N+VEGF-A/C (Figure 5A) andH+VEGF-A/C, long iso-
lated MECA-32+ blood vessel-like structures (marked by arrow-
heads in Figure 5B) that spanned several EBswere clearly detected.
In addition no differences were seen in the patterns of LEC differ-
entiation between EB cultures grown with or without VEGF-A/C,
either under normoxic or hypoxic conditions (Figures 3 and 5).
However, in all treatments except normoxia, it must be noted
that Prox1+ LECswere predominantly found surrounding regions
where blood vessel-like structures were observed. Certain regions
of the blood vessel-like structures also stained weakly for Prox1
(Figures 3 and 5).
DIFFERENTIAL ROLES OF EXTRACELLULAR MATRIX PROTEINS IN
PROMOTING INDUCTION OF LYMPHATIC VESSEL-LIKE STRUCTURES IN
E36.5-DAY-OLD EBs
Double immunostaining of E36.5-day-old EBs grownon collagen-
I (Figures 6 and 7) or laminin (Figure 8) was performed with
the BEC marker, MECA-32 and one of two LEC markers, Prox1
or LYVE1. Normoxic E36.5 EBs (Figure 6A) were not morpho-
logically different than the previous observations at E22.5. As
seen in Figure 6B, E36.5 hypoxic EBs grown on collagen-coated
plates promoted some Prox1+ lymphatic vessel-like structures
(arrowheads) but failed to promote MECA-32+ blood vessel-like
structures like those observed at E22.5 (Figure 3B). Furthermore
N+VEGF-A/C (Figure 6C) and H+VEGF-A/C (Figure 7) EBs
grown on collagen-coated plates developed the most prominent
lymphatic vessel-like structures, indicated by arrowheads, with
weak staining for MECA-32+ BECs also present within these
structures.
Embryoid bodies grown on laminin-coated plates under nor-
moxia (Figure 8A) or hypoxia (Figure 8B) exhibited only positive
staining for both BECs and LECs. N+VEGF-A/C EBs (Figure 8C)
formed ring-like structures, marked by arrowheads and exhib-
ited distinctive staining for LYVE1 andMECA-32. H+VEGF-A/C
(Figure 8D) promoted LEC differentiation mostly on the periph-
ery of differentiating EBs with no co-staining for MECA-32 in the
same region.
DISCUSSION
Using the mouse EB model, this present study demonstrates that
hypoxiawith an appropriate combinationof growth factors and/or
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Table 1 | Microarray analysis of selected genes of interest from a total of 357 genes that are at least twofold up- or down-regulated (p<0.05;
n =3) across age namely E10, E14, E17, and E20 when subjected to normoxic treatment.
Category p-Value E10N/E10N E14N/E10N E17N/E10N E20N/E10N Description
Growth Factors 0.010 1.00 0.90 2.03 3.16 Eph receptor A5. [Source: Uniprot/SPTREMBL; Acc: Q8C276]
0.024 1.00 1.52 2.01 1.54 Endothelin B receptor precursor (ET-B) [Source: Uniprot/
SWISSPROT; Acc: P48302]
0.040 1.00 2.32 2.26 2.02 Platelet-derived growth factor, C polypeptide; fallotein.
[Source: RefSeq; Acc: NM 019971]
0.010 1.00 2.83 3.73 3.83 Transforming growth factor, beta induced, 68 kDa. [Source:
RefSeq; Acc: NM 009369]
Contractile
Proteins
0.010 1.00 3.41 12.61 7.41 Myosin regulatory light chain 2, ventricular/cardiac muscle
isoform (MLC-2; MLC-2v). [Source: Uniprot/SWISSPROT;
Acc: P51667]
0.024 1.00 0.82 0.84 1.89 Actin, alpha skeletal muscle (Alpha-actin 1). [Source:
Uniprot/SWISSPROTAcc: P02568]
0.031 1.00 2.12 3.07 3.94 Troponin I, cardiac (Tnni3)
0.044 1.00 2.41 3.83 5.06 Troponin T, cardiac muscle isoforms (cTnT). [Source: Uniprot/
SWISSPROTAcc: P50752]
0.044 1.00 0.75 1.49 1.64 Troponin T, fast skeletal muscle isoforms. [Source: Uniprot/
SWISSPROTAcc: Q9QZ47]
0.014 1.00 0.83 1.44 2.77 Cardiac phospholamban (PLB). [Source: Uniprot/
SWISSPROT; Acc: P61014]
Transcription
Factors
0.034 1.00 0.53 1.24 2.29 Transcription factor SOX-10 (SOX-21; Transcription factor
SOX-M). [Source: Uniprot/SWISSPROT; Acc: Q04888]
Other Proteins 0.031 1.00 4.86 7.55 6.12 Procollagen, type III, alpha 1 (Col3al)
0.008 1.00 0.48 0.90 0.93 Procollagen, type XV. [Source: RefSeq; Acc: NM 009928]
0.035 1.00 1.63 1.24 2.18 Natriuretic peptides B precursor [Gamma-brain natriuretic
peptide; Brain natriuretic peptide (BNP)]. [Source: Uniprot/
SWISSPROT; Acc: P40753]
0.049 1.00 0.87 2.03 2.29 Coagulation factor VIII precursor (Procoagulant component).
[Source: Uniprot/SWISSPROT; Acc: Q06194]
0.010 1.00 2.30 5.98 6.10 Vitronectin precursor (Serum spreading factor; S-protein).
[Source: Uniprot/SWISSPROT; Acc: P29788]
0.012 1.00 0.97 1.55 2.52 Protocadherin alpha 12; cadherin-related neuronal receptor 5;
protocadherin alpha 13. [Source: RefSeq; Acc: NM 138663]
Fold changes across all time points are normalized to E10N.
ECM proteins can induce both blood and lymphatic developmen-
tal processes in differentiating EBs. While hypoxia along with
VEGF-A/C promotes blood vessel growth at a relatively early
time point (E22.5), EBs under similar conditions on a colla-
gen matrix favor lymphatic vessel growth at later time points
(E36.5).
It is well known that these developmental processes are very
carefully timed and orchestrated in embryonic development with
lymphangiogenesis being delayed behind angiogenesis (Sabin,
1902; Oliver and Alitalo, 2005). This concept was well corrob-
orated in the mouse EB model (Figures 3–8), where the data
show the presence of predominantly MECA-32+ blood vessel-like
structures at E22.5 and at a later time point (E36.5) prominent
lymphatic vessel-like structures (Prox1+/LYVE1+) are favored.
Nilsson et al. (2004) demonstrated that the effects of hypoxia on
blood vascular development were most prominent only during a
certain stage (E8–E12), and that the primitive vasculature needed
sufﬁcient time to develop before it could be remodeled by hypoxia.
This serves as a parallel explanation for the organized blood vas-
cular structures and the beginnings of LEC induction at E22.5,
followed later by organized lymphatic structures at E36.5. Further-
more, the microarray data for early EB development indicate that
while angiogenesis-related marker genes (VEGFR-1 andVEGF-A)
are upregulated in hypoxic conditions, lymphangiogenesis-related
gene expression is not signiﬁcantly altered at those time points
(Tables 1 and 2). It is possible that similar to development of the
blood vasculature, a critical window of time exists when hypoxia
could have a positive impact on lymphatic development. The data
presented in this study indicate that this discrete stage in lymph
vessel development may be conﬁned to later time points in EB
development, between E22–E36.
Liersch et al. (2006) tested the effects of growth factors, includ-
ing VEGF-A and VEGF-C on the development of lymphatic
structures in E21 and E27 normoxic EBs, while the effects of
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Table 2 | Microarray analysis of selected genes of interest from a total of 995 genes that are at least twofold up- or down-regulated (p<0.05;
n =3) across age namely E10–E20 when subjected to hypoxic treatment.
Category p-Value E10H/E10H E14H/E10H E17H/E10H E20H/E10H Description
Hypoxia induced 0.003 1 2.22 2.26 2.40 EROl-like. [Source: RefSeq; Acc: NM_015774]
Growth factors 0.028 1 0.85 0.87 0.45 Vascular endothelial growth factor receptor 1 precursor
(VEGFR 1; Tyrosine-protein kinase receptor FLT; FLT-1) [Source:
Uniprot/SWISSPROT; Acc: P35969]
0.045 1 1.59 0.93 2.08 Vascular endothelial growth factor A precursor (VEGF-A; Vascu-
lar permeability factor, VPF). [Source: Uniprot/SWISSPROT; Acc:
Q00731]
0.032 1 1.94 2.04 0.97 Ephrin type-A receptor 7 precursor (Tyrosine-protein kinase
receptor EHK-3) [Source: Uniprot/SWISSPROT; Acc: 061772]
0.047 1 0.70 0.43 0.59 Transforming growth factor beta 4 precursor (TGF-beta 4; Left
protein) [Source: Uniprot/SWISSPROT; Acc: O64280]
0.036 1 1.74 2.06 2.11 Insulin-like growth factor II precursor (IGF-II). [Source: Uniprot/
SWISSPROT; Acc: P09535]
Contractile
proteins
0.035 1 2.35 1.50 1.15 Myosin X (Myo 10)
0.021 1 3.01 4.43 5.84 Myosin heavy chain, cardiacmuscle alpha isoform (MyHC-alpha).
[Source: Uniprot/SWISSPROT; Acc: Q02566]
0.001 1 1.05 1.14 2.34 Actin, aortic smooth muscle (Alpha-actin 2). [Source: Uniprot/
SWISSPROT; Acc: P03996]
0.035 1 3.00 4.86 6.72 Actin. alpha cardiac. [Source: Uniprot/SWISSPROT: Acc: P04270]
0.011 1 1.05 2.97 2.52 Troponin I, slow skeletal muscle (Troponin I, slow-twitch isoform).
[Source: Uniprot/SWISSPROT; Acc: Q9WUZ5]
Transcription
factors
0.034 1 1.71 1.17 0.78 Neurogenic locus notch homolog protein 4 precursor (Notch 4)
[Source: Uniprot/SWISSPROT; Acc: P31695]
Cytokines/
chemokines
0.034 1 1.28 2.12 1.70 Interleukin-4 induced protein 1 precursor (FIG-1 protein; mFIG1).
[Source: Uniprot/SWISSPROT: Acc: O09046]
0.035 1 0.42 0.44 0.60 Interleukin-6 precursor (IL-6; Interleukin HP-1; B-cell hybridoma
growth factor). [Source: Uniprot/SWISSPROT; Acc: P08505]
Other proteins 0.011 1 0.75 1.19 2.44 CYR61 protein precursor (Cysteine-rich, angiogenic inducer, 61
(Insulin-like growth factor-binding protein 10; 3CH61). [Source:
Uniprot/SWISSPROT; Acc: P18406]
0.033 1 0.74 0.86 1.50 Myocyte-speciﬁc enhancer factor 2A. [Source: Uniprot/
SWISSPROT; Acc: Q60929]
0.029 1 0.95 0.67 0.47 Myocardin (SRF cofactor protein; Basic SAP coiled-coil transcrip-
tion activator 2). [Source: Uniprot/SWISSPROT; Acc: Q8VIM5]
0.036 1 2.73 2.74 1.74 Semaphorin 6A precursor (Semaphorin VIA; SEMA6A-1; Sem-
aphorin Q; Sema Q). [Source: Uniprot/SWISSPROT; Acc:
035464]
Fold changes across all time points are normalized to E10H.
hypoxia were not studied. Their results demonstrated that in the
absence of VEGF-A/C, E27 normoxic EBs was capable of forming
both blood and lymphatic structures, however, adding VEGF-A
or VEGF-C to the media further potently promoted lymphatic
vessel formation. In our study, upon addition of growth fac-
tors, E22.5 normoxic EBs (N+VEGF-A/C) formed MECA-32+
blood vessel-like structures similar to those seen by Liersch et al.
(2006). However organized lymphatic structures were lacking at
this stage. One explanation for this disparity could be that Liersch
et al. (2006) used twice the concentration of VEGF-C compared
to our study. This difference is signiﬁcant in light of the fact that a
more dominant effect was observed after the addition of VEGF-C
than with VEGF-A alone. Furthermore Kreuger et al. (2006) con-
ﬁrmed that a strong lymphangiogenic effect was not observed by
VEGF-A alone. Likewise other studies have documented a strong
synergism between VEGF-A and VEGF-C induction of lymphan-
giogenesis in cultured rat LECs (Whitehurst et al., 2006). Hence it
is plausible that a synergistic effect between VEGF-A and VEGF-
C triggers the commitment of BECs and LECs toward vessel
formation.
Hypoxia is a major physiological inducer of VEGF-A expres-
sion (Shweiki et al., 1992). Recent ﬁndings (Han et al., 2010) have
determined a novel mechanism via HIF-1β by which hypoxia is
capable of modulating the temporal expression ofVEGF receptors,
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Table 3 |The raw normalized microarray data for selected lymphatic markers at different ages (E10–E20) and oxygen treatments are given.
E10N E10H E14N E14H E17N E17H E20N E20H
Angiopoietin-2 1.007 0.906 1.166 1.071 0.944 1.04 0.918 0.712
Elk3 (NET) 1.242 1.335 1.598 1.355 0.874 0.881 0.84 0.803
EphB4 1.162 1.349 0.764 0.992 1.014 0.87 1.087 1.058
Ephrin B2 1.007 1.055 0.705 0.899 1.051 0.781 1.162 0.928
Fiaf (Angpt4) 1.111 1.053 1.274 1.114 0.935 0.827 0.988 0.878
FoxC1 0.96 0.797 1.298 1.243 1.078 0.976 1.026 0.685
FoxC2 0.913 0.894 0.887 0.972 0.934 1.007 0.985 1.026
Integrin α9 0.785 0.901 0.602 1.056 1.236 0.704 1.305 1.065
Integrin β1 0.653 0.762 1.043 0.995 0.857 1.116 0.965 1.03
Lyve1 0.932 0.841 1.105 1.122 1.095 0.981 1.171 0.873
Nrp2 1.106 0.8 1.662 1.249 1.092 0.955 0.973 0.568
Podoplanin 0.683 0.849 0.761 0.852 1.236 0.871 2.159 1.507
Prox1 0.982 1.031 1.031 1.163 0.994 0.695 0.952 0.785
SLC (CCL21) 0.997 1.127 0.739 0.839 0.994 1.08 1.003 1.075
Slp76 (Lcp2) 1.298 1.021 0.631 0.903 0.994 0.797 1.163 1.069
SOX18 1.027 0.949 1.107 1.021 0.933 0.908 0.943 0.97
Syk 1.07 1.205 1.57 1.184 1.199 0.993 0.858 1.026
Tie2 0.872 0.942 0.793 1.226 1.358 1.093 1.564 0.779
Trpv1 1.953 1.531 1.95 1.563 0.884 0.789 1.062 0.748
VEGF-C 1.215 1.024 1.365 1.329 1.058 1.024 0.952 0.807
VEGF-D 1.476 1.277 1.105 1.034 0.866 1.091 1.009 0.758
VEGFR-3 0.919 0.992 0.898 0.818 1.083 0.932 1.226 1.362
FIGURE 2 | Quantitative-PCR analyses of gene expression of vascular
marker (MECA-32) and LEC markers (LYVE1,VEGFR-3, Prox1) across
different days of EB development under conditions of normoxia (N)
and hypoxia (H). Fold changes are expressed as ratios of N/H. Fold
changes >1.0 indicates that expression of the genes of interest was
enhanced under normoxic conditions during all time points. Data represents
mean±SEM, *fold change signiﬁcantly greater than 1 (p<0.05; n =4).
which are consequently known to be critical for the formation
of vessel networks. Our microarray and qPCR data (Table 2
and Figure 2, respectively) corroborate well with the IHC data
(Figure 3) showing normoxic EBs committed toward both blood
(MECA-32+) and lymphatic (Prox1+) cell lineages prior to E22.5.
However normoxic cultures failed to form either blood or lym-
phatic vessel-like structures, indicating that these EBs have the
necessary potential but lack the guidance mechanism via VEGFR-
1 and VEGF-A to allow the more structured blood or lymphatic
FIGURE 3 | Double immunofluorescence staining of E22.5-day-old EBs.
Representative results from three different experiment sets for each
marker genes are shown. Lymphatic ECs (LECs) and vascular ECs (BECs)
are identiﬁed with Prox1 (green) and MECA-32 (red) markers respectively.
EBs were grown under normoxic or hypoxic conditions as described in the
Section “Materials and Methods.” (A) Normoxic EBs allowed differentiation
of both BECs and LECs but failed to form vessel-like structures. (B) Hypoxia
alone induces a network of blood vessel-like structures, indicated by
arrowheads and early differentiation of LECs. Images were taken at 40×
magniﬁcation (scale bar 30μm).
vessel formation. Conversely, hypoxic EBs had adequate VEGFR-1
andVEGF-A expression prior to E22.5, thus allowing angiogenesis
to occur, indicated by the presence of MECA-32+ blood vessel-like
structures (Figure 3). These blood vessel-like structures formed
despite the fact that MECA-32 expression was at least sixfold less
(Figure 2) thannormoxic cultures, suggesting a need for the timely
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FIGURE 4 | Digital images (without magnification) of EBs at E22.5
grown under (A) N+VEGF-A/C (VN) and (B) H+VEGF-A/C (VH)
treatments reveal contact of adjacent EBs to form cord-like structures,
as marked by arrowheads. Representative result from 4 different
experiment sets is shown.
FIGURE 5 | Double immunofluorescence staining of E22.5-day-old EBs
in the presence ofVEGF-A andVEGF-C. Representative images from
three different experiments sets for each marker genes are shown.
Arrowheads indicate MECA-32 positive blood vessel-like structures in
E22.5-day-old EBs grown under both VN (A) and VH (B) treatments. Prox1
positive LECs are in close proximity to the blood vessel-like structures.
Images were taken at 40× magniﬁcation (scale bar 30μm).
presence of guidance molecules, such as Angiopoietin-2 (Gale
et al., 2002; Veikkola and Alitalo, 2002) and EphrinB2 (Adams
et al., 1999; Makinen et al., 2005) for morphogenetic patterning
events.
Kreuger et al. (2006) demonstrated that E22 EBs that were cul-
tured on 3D collagen matrices and supplemented withVEGF-A/C
growth factors, failed to develop lymphatic structures after being
exposed to 8 days of hypoxia. Our results are in partial agree-
ment with these ﬁndings since E22.5 hypoxic EBs (Figure 3B)
in the absence of growth factors or a collagen-I matrix pre-
dominantly formed blood vessel-like structures, but not lym-
phatic vessel-like structures. This ﬁnding has also been recently
FIGURE 6 | Double immunostaining of E36.5-day-old EBs grown on
collagen matrices subjected to three treatment types (N, H,VN).
Representative images from three different experiments sets for each
marker genes are shown. (A) Normoxic EBs exhibited similar morphology
to that observed at E22.5, illustrating differentiation of both BECs
(MECA-32+) and LECs (Prox1+). (B) Hypoxia alone induces some lymphatic
vessel-like formation, as marked by arrowheads. (C) Normoxic EBs treated
with VEGF-A/C predominantly induces lymphatic vessel-like structures
(arrowheads). Images were taken at 40× magniﬁcation (scale bar 30μm).
FIGURE 7 | Double immunofluorescent staining of E36.5-day-old
hypoxic EBs grown on collagen-I coverslips and treated with
VEGF-A/C. Representative images from three different experiments sets
for each marker genes are shown. (A,B) Collagen-I promotes predominantly
the organization of LYVE1 positive lymphatic vessel-like structures (marked
by arrowheads) when stimulated under hypoxic and VEGF-A/C
environments. There are some traces of MECA-32 positive BECs along with
these lymphatic vessel-like structures. Unlike E22.5-day-old EBs, all four
types of treatment at E36.5 failed to form organized blood vessel-like
structures. Images were taken at 40× magniﬁcation (scale bar 30μm).
supported by Han et al. (2010), wherein they demonstrated that
hypoxia can promote EB vascular development independent of
VEGF. However hypoxia itself, in the absence or presence of
VEGF-A/C (Figures 6B and 7) stimulated the formation of a
few lymphatic vessel-like structures from EBs grown on collagen
matrices, but no blood vessel structures at E36.5. This mechanism
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is particularly relevant in the setting of tumor metastasis, where
effects of hypoxia are observed on VEGF-C induced lymphangio-
genesis (Schoppmann et al., 2006; Liang et al., 2008). Hence our
data suggest that a combination of factors including collagen-I
andVEGF-A/C helped toggle the switch from an initially predom-
inant angiogenic to a lymphangiogenic process. In comparison,
EBs grown on laminin alone (Figure 8) failed to form either dis-
tinctive blood or lymphatic structures, although they allowed BEC
and LEC differentiation. This is consistent with ﬁndings doc-
umented from previous studies (Davis and Senger, 2005) that
laminin blocks EC sprouting, but promotes EC differentiation.
Further support for our ﬁndings was provided by Jakobsson et al.
(2008) in which they demonstrated that although the composi-
tion of the vascular basement membrane in a murine EB model
consisted of ﬁbronectin, collagen and laminin, the knockdown
of laminin alone from ES cells still supported the formation of
vascular structures.
Collectively, our data demonstrate that while hypoxia alone
promotes angiogenic processes, in the presence of collagen matri-
ces lymphangiogenesis is favored in the mouse EB model at a later
developmental time point. Furthermore, VEGF-A and VEGF-C
induce both blood and lymphatic vessel-like structures during
the differentiation of EBs. Thus our data corroborate well with
other studies on lymphangiogenesis in mouse EB model (Nilsson
FIGURE 8 | E36.5-day-old EBs grown on laminin. EBs did not form
vessel-like structures when stimulated under normoxic, hypoxic and
VEGF-A/C environments. Representative data from three different
experiments sets for each marker genes are shown. (A) Normoxic EBs
grown on laminin did not show any distinguishable LEC phenotype, similar
to those grown on collagen-I. (B) Hypoxic EBs did not induce any vessel-like
structures within differentiating EBs. (C) N+VEGF-A/C EBs formed few
ring-like structures (arrowheads) within the core of the EB and showed
staining for LYVE1 in certain regions. (D) H+VEGF-A/C environments
promoted LEC (LYVE1+) differentiation mostly on the periphery of
differentiating EBs take. Images were en at 40× magniﬁcation (scale bar
30μm).
et al., 2004; Kreuger et al., 2006; Liersch et al., 2006). However
given the fact that in vivo developmental processes are multifac-
eted in nature in comparison to any in vitro models, using the
mouse EB model to study lymphatic vessel formation has sev-
eral limitations. As seen in Figure 9, the whole-mount mesenteric
preparation from a 3-month-old adult mouse exhibits a complex
network of lymphatic and blood vessel structures. Both vascular
and lymphatic systems show the presence of their respective EC
markers in association with vascular actin positive muscle cells.
Furthermore, the existence of initial lymphatics (ECs only) and
collecting lymphatics (with valves and presence of muscle cells)
are quite evident in the adult preparation. Though the mouse
EB model could recapitulate early lymphangiogenic events, the
intricate organization of the lymphatic system would be more
difﬁcult to mimic with this system. Nevertheless, the mouse EB
paradigm develops lymphatic vessel-like structures in this study
and in those shown by others (Nilsson et al., 2004; Kreuger et al.,
2006; Liersch et al., 2006). It should also be noted that advanced
3D reconstruction images are warranted to further validate the
vessel-like structures presented in this study. Nevertheless, the
event occurs only at a much later time point of EB development,
about E22–E36.5. These data clearly indicate that there are several
additional factors likely to be involved and that the timing of var-
ious stimuli has to be coordinated in differentiating EBs to mimic
conditions that occur in vivo. For example, Marino et al. (2011)
have recently shown that retinoic acid signaling plays an essen-
tial role in the earliest stages of lymphangiogenesis using mouse
EB model. In addition, having the knowledge through molecular
studies and knockout models of the relevance of several genes,
for example, FoxC2 for valve formation (Dagenais et al., 2004;
Petrova et al., 2004), Angiopoietin-2 (Gale et al., 2002; Veikkola
and Alitalo, 2002), and EphrinB2 (Adams et al., 1999; Makinen
et al., 2005) for the patterning of the lymphatic system would
FIGURE 9 |Triple immunofluorescence staining (20× magnification) of
whole-mount mesenteric preparations of 3-month adult mice
visualizing lymphatic vessels using LEC markers (A) LYVE1 (B)
podoplanin and blood vessels using BEC marker CD31. Representative
images from three different experiments sets for each marker genes are
shown. Muscle cells are identiﬁed with α-vascular actin. The adult mouse
mesentery demonstrates a complex network of blood and lymphatic
vessels of different sizes. Initial lymphatic vessels (LYVE1+/Podoplanin+) are
devoid of muscle cells (α-vascular actin−) whereas collecting lymphatic
vessels (LYVE1−/Podoplanin+) show a nice arrangement of muscle cells
(α-vascular actin+). Images were taken at 20× magniﬁcation (scale bar
12μm).
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be greatly beneﬁcial in applying the same information in the EB
model to understand the complexmechanisms of lymphatic vessel
development.
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